Latest News-Jiangsu Alphamab Biopharmaceuticals Co.,Ltd Mediaroom_Page

Alphamab Oncology will update the research results of several core pipeline products at the 2023 ESMO Annual Meeting

SUZHOU, China, Aug. 10, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that...

2023-08-10 09:02 3574

Alphamab Oncology updated clinical research data for KN026 in Combination with KN046 in HER2-Positive Solid Tumors at the ASCO 2023 annual meeting

* As of November 10, 2022, 26 patients with HER2-positive unresectable or metastatic solid tumors...

2023-06-06 09:06 3156

IND Application for Phase Ⅲ Registration Study of KN026 in Combination with Chemotherapy for the First-line Treatment of Breast Cancer Was Approved by CDE

SUZHOU, China, May 9, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmac...

2023-05-09 10:00 3239

Late-Breaking Research - Alphamab Oncology Presents Preclinical Results of KN052 at AACR 2023

SUZHOU, China, April 17, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced tha...

2023-04-17 14:01 2896

Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003

SUZHOU, China, March 16, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced tha...

2023-03-16 09:58 3259

Alphamab Oncology to Present the Preclinical Results of PD-L1/OX40 Bispecific Antibody KN052 at AACR 2023

SUZHOU, China, March 15, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced tha...

2023-03-15 10:06 3395

Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer at SABCS 2022

* As of August 18, 2022，the confirmed ORR for 55 evaluable subjects was 76.4% and DoR was 24.0 mo...

2022-12-12 15:51 2602

Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer at SABCS 2022

* As of Sep 10, 2022, 20 patients completed the surgery and pathological evaluation, tpCR rate we...

2022-12-12 15:00 2814

Alphamab Oncology Presented Final Analysis of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at SABCS 2022

* As of August 21, 2022, the ORR from 25 efficacy evaluable TNBC patients was 44.0%, the DCR was ...

2022-12-12 10:33 3149

Better treatments for breast cancer! Latest Clinical Data of Bispecific Antibodies will be presented at SABCS 2022 By Alphamab Oncology

SUZHOU, China, Nov. 22, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that...

2022-11-22 09:18 4690

Data from KN046 in Patients with metastatic NSCLC who failed first line treatment or prior EGFR-TKIs Presented at ESMO 2022

* 64 patients with metastatic NSCLC who had failed first-line treatment were enrolled, the median...

2022-09-14 09:11 2671

Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line（1L）treatment for NSCLC at ESMO 2022

* 2-year survival data of this study were presented: KN046 combined with platinum doublet chemoth...

2022-09-14 09:04 2553

Updated Data Presented for KN026 comboKN046 in 1st Line HER2-Positive Gastric/Gastroesophageal Junction Cancer (GC/GEJ)

* As of January 30, 2022,31 patients with HER2-positive unresectable locally advanced or metastat...

2022-09-14 09:01 2627

First Patient Dosed in Phase II Study of KN046 Combined with Axitinib for the First Line Treatment of Advanced Non-Small Cell Lung Cancer

SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the f...

2022-08-09 11:18 3863

Latest News